• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Rapid Dose closes first tranche of $5M financing

August 10, 2022 By Sean Whooley

Rapid Dose Therapeutics LogoRapid Dose Therapeutics announced today that it closed on the first tranche of a previously announced private placement financing.

Burlington, Ontario-based Rapid Dose develops drug delivery products, including the flagship QuickStrip thin, orally dissolvable film that was designed to be infused with a number of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient.

The company closed the $230,000 tranche of the financing, which is worth up to $5 million in gross proceeds. The placement consists of up to 5,000 units at $1,000 per unit. Each unit consists of $1,000 principal amount of unsecured convertible notes and 100 common share purchase warrants of the company. In this first tranche, 230 units were purchased, according to a news release.

Rapid Dose’s notes have a maturity date of 24 months from the closing date and bear interest from their date of issue at 10% per annum. further 2% per annum interest payment will be made annually in cash or in common shares of the company as determined by the company. The notes are convertible into common shares at a conversion price of 40¢ per common share.

The company plans to use proceeds from the financing to continue the research and development of oral thin films embedded with vaccines and mRNA as the active ingredients.

Other uses for the funds raised include financing capital expansion projects for specific revenue streams for working capital supporting revenue streams coming online and costs and fees for the financing itself.

Filed Under: Business/Financial News, Drug-Device Combinations, Funding Roundup, Pharmaceuticals, Research & Development Tagged With: Rapid Dose Therapeutics

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS